| 摘要: |
| 近年来，以程序性死亡蛋白-1（PD-1）/程序性死亡蛋白配体-1（PD-L1）抑制剂为代表的免疫治疗对肺癌显示出明显疗效，但在不同的肺癌患者中PD-1/PD-L1抑制剂的疗效存在显著差异。研究发现外泌体PD-L1（ePD-L1）可以代替肺癌细胞PD-L1抑制T细胞活化，产生免疫抵抗，同时还能将PD-L1转移到次级细胞发挥免疫耐受作用，影响免疫治疗的效果。本文对外泌体及ePD-L1的分离与检测方法、ePD-L1的免疫抑制作用及ePD-L1在肺癌进展和免疫治疗中的作用机制进行综述。 |
| 关键词: 外泌体 程序性死亡蛋白-1 程序性死亡蛋白配体-1 肺肿瘤 免疫疗法 |
| DOI：10.16781/j.CN31-2187/R.20210819 |
| 投稿时间：2021-08-19修订日期：2022-04-12 |
| 基金项目:国家自然科学基金（82070036）. |
|
| Exosomal programmed death-1 in lung cancer: research progress |
| HU Jia-xun,TANG Hao* |
(Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200003, China
*Corresponding author) |
| Abstract: |
| In recent years, immunotherapy represented by programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has shown remarkable efficacy for lung cancer. However, there are significant differences in the efficacies of PD-1/PD-L1 inhibitors in different patients with lung cancer. Studies have found that exosomal PD-L1 (ePD-L1) can replace the PD-L1 from lung cancer cells to inhibit the activation of T cell and produce immune resistance. At the same time, it can transfer PD-L1 to secondary cells to play the role of immune tolerance and affect the efficacy of immunotherapy. This paper reviews the methods of separation and detection of exosomes and ePD-L1, the immunosuppressive effect of ePD-L1, and the mechanism of ePD-L1 in the progress of lung cancer and immunotherapy. |
| Key words: exosomes programmed death-1 programmed death-ligand 1 lung neoplasins immunotherapy |
